Michelle Davies

Equity Capital Markets

• Destiny Pharma plc, an AIM-quoted clinical stage biotechnology company focused on the development of novel medicines to prevent life threatening infections, on its successful £6.45 million equity fundraising via a placing, subscription and open offer (March 2022).
• Sensyne Health PLC, on its £11.35 million financing (January 2022).
• Arecor Therapeutics plc, a biopharmaceutical company on its AIM IPO and £20 million equity fundraise through a placing (June 2021).
• NCC Group PLC, a FTSE 250 UK-listed cyber and software resilience business, on its £72.6 million placing in connection with its acquisition of the Intellectual Property Management business of Iron Mountain Inc. (June 2021).
• Sensyne Health PLC, an AIM-Listed UK clinical artificial intelligence company on its £27.5 million placing, subscription and open offer (January 2021).
• Redx Pharma PLC, an AIM-quoted biotech company focused on the discovery and development of novel targeted medicines for the treatment of cancer and fibrotic disease, in connection with a placing and open offer of shares, to raise £27.7 million (December 2020).
• Destiny Pharma plc, an AIM-quoted clinical stage biotechnology company focused on the development of novel medicines to prevent life threatening infections, on its successful £10.4 million equity fundraising which comprised of a placing, subscription and open offer (November 2020).

Mergers and Acquisitions

• NCC Group PLC, a FTSE 250 UK-listed cyber and software resilience business, on its $220 million acquisition of the Intellectual Property Management business of Iron Mountain Inc. (June 2021).
• Reliance New Energy Limited, a wholly-owned subsidiary of Reliance Industries Limited, on its acquisition of substantially all of the assets of Lithium Werks for a total of US$61 million, including funding for future growth.
• Odyssey Therapeutics, Inc., a biotechnology company pioneering next generation precision immunomodulators and oncology medicines, in its acquisition of Rahko, a quantum machine learning drug discovery platform (December 2021).
• Microsoft Corporation on the UK corporate law aspects of its US$7.5 billion acquisition of ZeniMax Media.

Other

• A diagnostic company focused on immune-regulated conditions in a $40 million follow-on offering.
• Advised Elanco Animal Health in connection with the divesture of Elanco’s Drontal and Profender products in multiple jurisdictions to Vetoquinol.